# US 12,180,476 B2 · Use of PIWI-interacting RNA piR-hsa-211106

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,180,476 B2
- Document ID: US12180476B2
- Status: Granted
- Kind: B2
- Application number: 17/666,262
- Filed: 2022-02-07
- Published: 2023-08-10
- Granted: 2024-12-31
- Earliest claimed: 2022-02-07
- Applicants: Qingdao University
- Inventors: Wenhua Xu; Yongmei Liu; Yanhan Dong; Jinning Gao; Xiaodan Hao; Zibo Wang; Meng Li
- Web page: https://patentgrep.com/patent/US12180476B2

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 35/00: Antineoplastic agents
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 2310/10: Type of nucleic acid
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2320/31: Combination therapy
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In the field of biomedical technology, a PIWI-interacting RNA piR-hsa-211106 is used to prepare a targeted therapeutic drug for inhibiting proliferation of lung adenocarcinoma cells. A mechanism is as follows: after the PIWI-interacting RNA piR-hsa-211106 is constructed into an agonist or a transformant, the agonist or the transformant inhibits a tricarboxylic acid cycle process by down-regulating an expression of a pyruvate carboxylase, inhibits an energy metabolism, promotes apoptosis of the lung adenocarcinoma cells, thus inhibits growth of the lung adenocarcinoma. The PIWI-interacting RNA piR-hsa-211106 directly acts on a target site and does not produce toxic and side effects and an off-target phenomenon. Large amounts of analysis and in-vivo and in-vitro experiments show that the PIWI-interacting RNA piR-hsa-211106 has high credibility and a remarkable treatment effect, and provides a new research direction for anti-tumor therapy of lung adenocarcinoma.

## Claims

### Claim 1

A method of inhibiting proliferation of lung adenocarcinoma cells A549 or HCC2279, comprising administering a therapeutic drug to the A549 or HCC2279 lung adenocarcinoma cells, wherein the therapeutic drug comprises PIWI-interacting RNA piR-hsa-211106 or a variant thereof that is greater than 80% identical to the entire length of SEQ ID NO:1.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the PIWI-interacting RNA piR-hsa-211106 or the variant thereof is encoded in a viral vector selected from the group consisting of an adenovirus, a lentivirus and an adeno-associated virus.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the nucleotide sequence of PIWI-interacting RNA piR-hsa-211106 is set forth in SEQ ID NO:1.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the method comprises transferring the PIWI-interacting RNA piR-hsa-211106 or the variant thereof into lung adenocarcinoma cells A549 or HCC2279 and determining an effect of the PIWI-interacting RNA piR-hsa-211106 or variant thereof on cell proliferation activity by detecting proliferation indicators of lung adenocarcinoma cells by a CCK8 kit and EdU staining.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the method comprises determining an effect of the PIWI-interacting RNA piR-hsa-211106 or the variant thereof on cell migration capacity by detecting migration indicators of lung adenocarcinoma cells.